Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918199 | PMC |
| http://dx.doi.org/10.2337/dc21-2372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-Widefield and Early Treatment Diabetic Retinopathy Study 7-Field Grading of Diabetic Retinopathy.
JAMA Ophthalmol
September 2024
Department of Biostatistics and Bioinformatics, Biostatistics Center, The George Washington University, Washington, DC.
Importance: High concordance in diabetic retinopathy (DR) outcomes between 7-field (7F) and ultra-widefield (UWF) images would allow for combining longitudinal assessments based on the 2 modalities both in clinical studies and clinical care.
Objective: To compare 7F and UWF imaging with regard to DR severity and the associations of DR severity with risk factors, such as hemoglobin A1c, age, diabetes duration, and sex.
Design, Setting, And Participants: This cross-sectional study describes the outcomes of the randomized clinical Diabetes Control and Complications Trial (DCCT) and its subsequent observational study, the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
Ann Intern Med
January 2023
Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).
GRADE Study Research Group; Nathan DM, Lachin JM, Buse JB, et al. N Engl J Med. 2022;387:1075-88.
View Article and Find Full Text PDFIn type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Ann Intern Med
January 2023
Tower Health/Reading Hospital, West Reading, Pennsylvania, USA (K.B., A.A.D.).
GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, et al. N Engl J Med. 2022;387:1063-74.
View Article and Find Full Text PDFResponse to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448.
Diabetes Care
January 2023
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!